What is Mesalamine
Approved as Treatment by the FDAMesalazine, otherwise called Rowasa, is approved by the FDA for 2 uses which include Ulcerative Colitis and Crohn Disease .
When to interrupt dosageThe proposed dose of Mesalamine is contingent upon the specified disorder. The amount of dosage also relies upon the approach of administration outlined in the table below.
WarningsMesalamine has eight contraindications, so it should not be administered when one is going through any of the conditions detailed in the ensuing table.Mesalamine Contraindications
Mesalamine Novel Uses: Which Conditions Have a Clinical Trial Featuring Mesalamine?Currently, 96 trials are being conducted to assess the potential of Mesalamine to alleviate symptoms of Ulcerative Colitis.
Mesalamine Reviews: What are patients saying about Mesalamine?
Patient Q&A Section about mesalamineThese questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is mesalamine prescribed for?
"Mesalamine is a medication used to treat and prevent episodes of ulcerative colitis, a condition characterized by inflammation of the bowels. Mesalamine works by reducing inflammation and other symptoms associated with the disease. This medication is only available with a prescription from a doctor."
When should you take mesalamine?
"Take the Asacol® HD tablet on an empty stomach, at least 1 hour before or 2 hours after a meal. The Lialda® tablets should be taken with food. All other brands of capsules and tablets can be taken with or without food."
What are the long term effects of taking mesalamine?
"These side effects include worsening colitis; renal toxicity such as interstitial nephritis and nephrotic syndrome; pulmonary toxicity such as interstitial lung disease and fibrosis, bronchiolitis obliterans, pulmonary granulomatosis, and eosinophilic pleural effusion; pericarditis, pancreatitis, hair loss, and Stevens-Johnson syndrome."
How long can you stay on mesalamine?
"The long-term safety and tolerability of mesalamine granules (MG) therapy was evaluated in the maintenance of UC remission in this study. Studies evaluating different oral mesalamine formulations that came before this one did not exceed a duration of 14 months."